Skip to main content

Nausea and Vomiting, Chemotherapy-Induced

12
Pipeline Programs
2
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 19 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
12 programs
9
1
2
CasopitantPhase 31 trial
Oral CasopitantPhase 31 trial
GW679769Phase 21 trial
CasopitantPhase 11 trial
CasopitantPhase 11 trial
+7 more programs
Active Trials
NCT00404274Completed97Est. Mar 2007
NCT00437229Completed37Est. May 2007
NCT00460707Completed85Est. Aug 2007
+9 more trials
GSK
GSKLONDON, United Kingdom
8 programs
CasopitantPHASE_1
CasopitantPHASE_1
DocetaxelPHASE_1
GW679769PHASE_1
Oral GW679769PHASE_1
+3 more programs

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ViiV HealthcareCasopitant
ViiV HealthcareOral Casopitant
ViiV HealthcareGW679769
ViiV Healthcareondansetron
ViiV Healthcarecasopitant
ViiV HealthcareDocetaxel
ViiV HealthcareCasopitant 150 mg
ViiV HealthcareCasopitant
ViiV HealthcareGW679769
ViiV HealthcareCasopitant
ViiV Healthcareketoconazole
ViiV HealthcareOral GW679769

Clinical Trials (12)

Total enrollment: 2,601 patients across 12 trials

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

Start: Mar 2008Est. completion: Apr 2009710 patients
Phase 3Completed

A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Start: Nov 2006Est. completion: Oct 2007810 patients
Phase 3Completed

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Start: Dec 2004Est. completion: Jan 2006722 patients
Phase 2Completed

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Start: Aug 2011Est. completion: Dec 201160 patients
Phase 1Completed

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Start: Jul 2007Est. completion: Sep 200716 patients
Phase 1Completed

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

Start: May 2007Est. completion: Jul 200812 patients
Phase 1Completed

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

Start: Apr 2007Est. completion: Aug 200785 patients
Phase 1Completed

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Start: Feb 2007Est. completion: May 200737 patients
Phase 1Completed

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

Start: Nov 2006Est. completion: Jan 200712 patients
Phase 1Completed

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Start: Nov 2006Est. completion: Mar 200797 patients
Phase 1Completed

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

Start: Oct 2006Est. completion: Jan 200715 patients
Phase 1Completed

Cyclophosphamide Drug Interaction Study In Cancer Patients

Start: Aug 2005Est. completion: Oct 200925 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.